Antares Pharma Inc (ATRS)

2.43
0.04 1.60
NASDAQ : Health Care
Prev Close 2.47
Open 2.45
Day Low/High 2.40 / 2.50
52 Wk Low/High 0.67 / 2.25
Volume 394.28K
Avg Volume 947.70K
Exchange NASDAQ
Shares Outstanding 155.09M
Market Cap 400.12M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Injecting Some Testosterone Into the Portfolio

We're initiating a position in drug-delivery system developer Antares Pharma, which we think can double from current levels.

2 Bargain Stocks Boasting Big Insider Buys

While there are many reasons why insiders may sell a stock, there's really only one reason they purchase on the open market -- to make money.

Antares Pharma Announces Submission Of New Drug Application For Quickshot® Testosterone

Antares Pharma Announces Submission Of New Drug Application For Quickshot® Testosterone

The Company's First New Drug Application Utilizing QuickShot® Technology

First Week of August 2017 Options Trading For Antares Pharma (ATRS)

First Week of August 2017 Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options begin trading this week, for the August 2017 expiration.

Antares Pharma Announces The Successful Completion Of Teva's Decentralized Procedure For Teriparatide Injection In Europe

Antares Pharma Announces The Successful Completion Of Teva's Decentralized Procedure For Teriparatide Injection In Europe

Teriparatide Injection Represents the First Product Approved in Europe Utilizing Antares' Multi-Dose Pen Technology

Antares Pharma Reports Third Quarter 2016 Financial And Operating Results

Antares Pharma Reports Third Quarter 2016 Financial And Operating Results

Record Product Sales Drive Third Quarter Results

Antares Pharma Announces Multiple Presentations At The Sexual Medicine Society Scientific Annual Meeting

Antares Pharma Announces Multiple Presentations At The Sexual Medicine Society Scientific Annual Meeting

QuickShot® Testosterone Data Has Been Selected for Both Oral and Poster Presentations

Antares Pharma Announces Completion Of The QuickShot Testosterone Clinical Program

Antares Pharma Announces Completion Of The QuickShot Testosterone Clinical Program

Analysis of 26 Week Safety Data From Study QST-15-005 Completed, NDA Submission Remains on Track for Fourth Quarter 2016

Teva Discusses EpiPen Comps as Host of Generics Unveiled

Teva Discusses EpiPen Comps as Host of Generics Unveiled

The drug company has several generic drugs that will compete with the likes of Pfizer's Viagra and Valeant's Acanya.

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Antares Pharma Reports Second Quarter 2016 Operating And Financial Results

Significant Growth in Product Sales Drive Second Quarter Results

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva And Antares Pharma Announce Launch Of Generic Imitrex® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc.

Antares Pharma Announces Settlement Of Patent Litigation For Key Alliance Business Product

Antares Pharma Announces Settlement Of Patent Litigation For Key Alliance Business Product

Settlement Between AstraZeneca and Teva Allows Teva to Commercialize Its Generic Version of BYETTA on October 15, 2017

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 21.61 "days to cover" versus the median component at 6.18.

Antares Pharma Announces Update To QuickShot Testosterone Clinical Program

Antares Pharma Announces Update To QuickShot Testosterone Clinical Program

Last Patient Completes Treatment in QuickShot Supplemental Safety Study QST-15-005

Short Interest Moves 16.5% Lower For ATRS

Short Interest Moves 16.5% Lower For ATRS

The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 1,852,957 share decrease in total short interest for Antares Pharma Inc. , to 9,381,683, a decrease of 16.49% since 04/15/2016.

Antares Pharma Reports First Quarter 2016 Operating And Financial Results

Antares Pharma Reports First Quarter 2016 Operating And Financial Results

Total Revenues of $12.3 million increased 48% Over Q1 2015

Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Now Available - 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml

TheStreet Quant Rating: D (Sell)